SS-31 is another name for elamipretide, a small peptide studied for its effects on mitochondria. It is no longer accurate to describe it simply as “unapproved”: in September 2025, the FDA granted accelerated approval to Forzinity, an elamipretide medicine, to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. That is a specific rare-disease indication, not approval for general fatigue, weight loss or anti-aging. [1]
Keep three things separate: the approved prescription product, investigational uses in other illnesses and research vials sold as SS-31. Evidence for one doesn’t automatically validate another.
Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see SS-31 (10 mg Vial) Dosage Protocol, SS-31 (30 mg Vial) Dosage Protocol, and SS-31 (50 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.
What SS-31 does in mitochondria
Elamipretide is a four-amino-acid peptide that binds cardiolipin in the inner mitochondrial membrane. Its prescribing information describes effects on mitochondrial structure and function. [2] Mitochondria help cells produce ATP, a molecule used to supply energy for cellular work. Cardiolipin is a membrane lipid involved in keeping that system functioning. [5]
That makes mitochondrial function a sensible research target. It does not make a laboratory finding about energy production the same thing as feeling less tired, walking farther or living longer. Those outcomes need to be tested separately in people.
For SS-31, that separation is particularly important: human trials have not all pointed in the same direction. A biological effect can be measurable without producing the clinical improvement someone hopes for.
Forzinity approval: what it covers and what it does not
Barth syndrome is a rare genetic disorder associated with changes in the TAFAZZIN gene and cardiolipin processing. It can affect the heart and skeletal muscles and can cause low white-blood-cell counts. It is not another name for ordinary tiredness or age-related mitochondrial decline. [5]
The approval relied on improved knee-extensor strength, an intermediate clinical endpoint, in a small development program. The randomized portion did not demonstrate improvement in its main walking-distance and fatigue endpoints; strength improvements emerged during the longer open-label extension. Continued approval may depend on a confirmatory trial establishing clinical benefit. [1]
“Accelerated approval” is therefore neither “no evidence” nor “every benefit is settled.” It is a particular regulatory pathway with remaining questions. It also does not make every bottle labeled SS-31 an FDA-approved medicine.
What human studies actually found
| Population and study | Result and limitation |
|---|---|
| Barth syndrome | A 12-person trial with an extension supported Forzinity’s accelerated approval. The favorable strength findings do not establish an anti-aging benefit or a treatment for all mitochondrial diseases. [1] |
| Primary mitochondrial myopathy | MMPOWER-3 randomized 218 people for 24 weeks. Elamipretide did not improve the primary walking-distance or fatigue outcomes compared with placebo. [3] |
| Older adults with low muscle mitochondrial function | A 39-person study found a short-term change in an ATP-production measure after an infusion, but no significant improvement in muscle fatigue resistance and no difference at day seven. [4] |
The negative myopathy trial belongs in the picture
MMPOWER-3 was a randomized, double-blind phase 3 trial in people with genetically confirmed primary mitochondrial myopathy. There were 109 participants in each group. After 24 weeks, the difference in six-minute walking distance was not statistically significant, and the fatigue outcome also failed to show a benefit. [3]
These findings do not prove that the molecule has no biological activity. They do mean it would be misleading to describe SS-31 as an established treatment for fatigue across mitochondrial disorders. A plausible mechanism cannot substitute for a failed clinical endpoint.
The older-adult study measured biology, not longevity
The 2021 trial enrolled 39 adults aged 60 to 85 who had low mitochondrial function in a hand muscle. Researchers measured the response to a single two-hour infusion. The relative change in maximum ATP-production capacity met statistical significance, while the absolute-change comparison narrowly did not. There was no significant improvement in the tested muscle’s fatigue resistance. [4]
This is interesting early human research. It is not evidence that a home injection course reverses aging, boosts athletic performance or creates lasting energy. The study did not test lifespan, and the measured difference was absent at the seven-day follow-up. [4]
Quick check: if ATP production increases, must fatigue improve?
No. A biological measurement and a symptom are different outcomes. In the older-adult study, the ATP finding did not come with a significant improvement in the measured fatigue resistance. A claim about feeling better needs its own supporting result. [4]
SS-31 side effects and safety
Injection-site reactions are the most common adverse reactions in Forzinity’s labeling. Serious allergic reactions have also been reported. Severe kidney impairment can require a prescribing adjustment; the product contains benzyl alcohol and must not be used in neonates. These are meaningful precautions, not a description of a risk-free “cellular support” supplement. [2]
In MMPOWER-3, adverse events were generally mild to moderate and the study described treatment as well tolerated. That finding applies to a monitored trial population and does not establish the safety of online research products, indefinite use, or combinations with other investigational peptides. [3]
Tell a clinician about existing conditions and all other products being used. Serious symptoms, particularly breathing difficulty or a rapidly developing allergic reaction, need urgent care. Unexplained persistent fatigue also deserves an assessment rather than an assumption that mitochondria are the cause.
Why there is no general SS-31 dosage in this article
The Forzinity label specifies a prescription regimen for its approved Barth syndrome population. It describes a ready-made injectable solution, not a powder that the patient reconstitutes. That regimen should not be converted into a universal wellness protocol or copied onto a differently formulated research vial. [2]
The research itself also used different settings and routes: MMPOWER-3 studied repeated subcutaneous treatment, while the older-adult experiment used a short intravenous infusion. Mixing those results into one online “cycle” would create instructions that neither trial tested. [3] [4]
Common questions
Is SS-31 FDA-approved?
Forzinity, containing elamipretide, has accelerated approval for a defined Barth syndrome use. That is not blanket approval for all SS-31 products or for every proposed use. [1]
Can SS-31 help with weight loss?
The trials summarized here do not establish weight-loss treatment. Their outcomes concerned muscle strength, walking, fatigue or muscle energy measurements. A claim about mitochondrial function should not be relabeled as proof of fat loss. [1] [3] [4]
Is it a substitute for MOTS-c or another peptide?
A shared interest in metabolism does not make different compounds interchangeable. The SS-31 findings described here also do not establish a safe or effective combination with MOTS-c, NAD+ products or other substances. Each proposed combination would need its own evidence.
How quickly should someone expect an effect?
There is no single evidence-based answer across these uses. A measurement taken immediately after an infusion is not a timeline for symptom relief. The longer trials used different populations and endpoints, including outcomes that did not improve. [3] [4]
SS-31’s clinical history includes a medicine approved for a narrowly defined condition. Other studies have encouraging and negative findings. Read each result in its condition-specific context, not as a promise of “mitochondrial repair for everyone.” A qualified healthcare professional can help with treatment questions.
Related dosage protocols and research
Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable.
Matching dosage protocols
Related protocols and comparisons
Further research context
References
- FDA. Drug Trials Snapshots: Forzinity. Approval September 19, 2025. Checked October 6, 2026.
- Forzinity prescribing information. DailyMed. Checked October 6, 2026.
- Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023.
- Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021.
- MedlinePlus Genetics. Barth syndrome.